HomeAI · summaries
Storia in 4 fonti
Supernus, Indivior merge to create CNS-focused company and expand BD opportunities
Two growing companies, Supernus Pharmaceuticals and Indivior Pharmaceuticals, have
Confronto fonti
4 prospettive sulla stessa storiaTimeline cronologica
- ·
biopharmadive.com
Supernus, Individor merge to beef up brain drug portfolio
The transaction combines two companies marketing nearly a dozen neurological drugs that bring in steady, but not blockbuster sales for conditions such as opioid use disorder and…
- ·
endpoints.news
Supernus, Indivior to merge and form CNS-focused drugmaker
Supernus and Indivior agree to an all-stock merger creating a $2.2B CNS biopharma led by CEO Jack Khattar, closing Q4 2026.
